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Abstract 
 
Oxidative biocatalytic reactions performed by cytochrome P450 enzymes (P450s) are of high 
interest for the chemical and pharmaceutical industries. CYP267B1 is a P450 enzyme from 
myxobacterium Sorangium cellulosum So ce56 displaying a broad substrate scope. In this 
work, a search for new substrates was performed, combined with product characterization, 
and a structural analysis of substrate-bound complexes using X-ray crystallography and 
computational docking. The results demonstrate the ability of CYP267B1 to perform in-chain 
hydroxylations of medium-chain saturated fatty acids (decanoic acid, dodecanoic acid and 
tetradecanoic acid) and a regioselective hydroxylation of flavanone. The fatty acids are 
mono-hydroxylated at different in-chain positions, with decanoic acid displaying the highest 
regioselectivity towards ω-3 hydroxylation. Flavanone is preferably oxidized to 3-
hydroxyflavanone. High-resolution crystal structures of CYP267B1 revealed a very spacious 
active site pocket, similarly to other P450s able to convert macrocyclic compounds. The 
pocket becomes more constricted near to the heme, and is closed off from solvent by residues 
of the FG helices and the B-C loop. The crystal structure of the tetradecanoic acid-bound 
complex displays the fatty acid bound near to the heme, but in a non-productive 
conformation. Molecular docking allowed modeling of the productive binding modes for the 
four investigated fatty acids and flavanone, as well as of two substrates identified in a 
previous study (diclofenac and ibuprofen), explaining the observed product profiles. The 
obtained structures of CYP267B1 thus serve as a valuable prediction tool for substrate 
hydroxylations by this highly versatile enzyme and will encourage future selectivity changes 







Cytochromes P450 (P450s / CYPs) are heme-thiolate containing monooxygenases present in 
all domains of life, with >300 thousand sequences identified so far [1]. Physiologically, P450 
enzymes are involved in human steroid metabolism, biotransformation of drugs and other 
xenobiotics, or biosynthesis of secondary metabolites [2,3]. They catalyze a wide spectrum of 
oxidation reactions using molecular oxygen and incorporate a single oxygen atom into the 
organic substrate, with the second oxygen atom being reduced to water [4]. To perform the 
monooxygenase reaction, P450s require electrons to be delivered in order to generate the 
highly reactive ferryl-oxo species (Compound I) in the P450 catalytic cycle. Thus, they need 
the help of redox partner proteins which oxidize NAD(P)H and transfer the reducing 
equivalents to the heme-containing P450 [5,6]. In white biotechnology, P450 enzymes are 
considered attractive biocatalysts for their ability to insert a single oxygen atom into inert 
C-H bonds, in a selective and controlled manner under mild conditions. In general, bacterial 
P450 enzymes are more attractive for biocatalytic conversions than their eukaryotic 
counterparts, due to their easier handling characteristics, like efficient soluble gene 
expression in E. coli, or higher stability. Most importantly, however, the biocatalytic potential 
of bacterial CYPs lies in their remarkable ability to oxidize substrates in a highly regio- and 
stereospecific manner [7-10].  
To make better use of the P450 catalytic power and versatility to perform synthetically 
difficult reactions, an expansion of the panel of functionally and structurally 
well-characterized microbial P450s is desired. Thus far, only a few bacterial P450s have been 
identified which naturally possess a broad substrate scope like members of CYP154 family 
(e.g. CYP154E1 from Thermobifida fusca XY, [11]), CYP109 family [12,13] and the enzyme 
CYP116B4 from Labrenzia aggregate [14]. More often the natural substrate spectrum of 
bacterial P450s has been altered by protein engineering strategies to allow conversion of 
non-physiological substrates. The most prominent example is the P450 BM3 (CYP102A1) 
from Bacillus megaterium, a highly active fatty-acid hydroxylase, for which the vast 
availability of structural information facilitated successful engineering towards oxidation of 
many different classes of chemicals like steroids [15], alkanes [16], alkaloids [17], terpenes 
[18] or polycyclic aromatic hydrocarbons [19]. Notwithstanding the successes of rational 
protein engineering, the identification and use of wild-type P450s accepting a broad range of 
substrates is advantageous, as it will circumvent time-consuming procedures like the 
necessity to generate massive amounts of mutants and tedious screening.  
A recently characterized bacterial P450 with an exceptionally broad substrate scope is 
CYP267B1 from the myxobacterium Sorangium cellulosum So ce56 [20], one of the 21 P450 
monooxygenases identified in this bacterium [21]. Without the need for any protein 
engineering, the enzyme was shown to readily accept different classes of substrates, from 
small carotenoid-derived aroma compounds or sesquiterpenes [22,23] to sterically 
challenging molecules like epothilone D [24]. CYP267B1 was also shown to oxidize several 
structurally diverse drugs, such as diclofenac, ibuprofen, oxymetazoline or repaglinide, as 
well as antidepressant or antipsychotic drugs like amitriptyline, chlorpromazine, imipramine 
or promethazine [25,26]. Thus, the wild type CYP267B1 shows high catalytic variability, 
catalyzing not only aliphatic, allylic and aromatic hydroxylations, but also sulfoxidation or 
epoxidation [22,26]. Despite the wealth of biochemical data available for this versatile P450, 
its catalytic potential towards different substrate classes might not be fully explored and its 
structural properties have not been investigated yet.  
In this study, the hydroxylation activity of CYP267B1 towards two new classes of 
substrates, saturated medium-chain fatty acids (decanoic acid, dodecanoic acid and 
tetradecanoic acid) and a flavonoid compound (flavanone), was demonstrated for the first 
time, their binding affinities were evaluated and reaction products identified. Structural data 
obtained with X-ray crystallography, supplemented by molecular docking results, allowed us 
to map the active site geometry of CYP267B1 and to predict the binding modes of currently 
and previously identified substrates. Overall, our results highlight the vast biocatalytic 
applicability of CYP267B1 and provide crucial structural insights explaining its broad 
substrate recognition.  
 
 
Materials and methods 
Chemicals and strains 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) and 5-aminolevulinic acid (δ-ALA) were 
purchased from Carbolution Chemicals (Saarbrücken, Germany). Bacterial media were 
obtained from Becton Dickinson (Heidelberg, Germany). The Escherichia coli (E. coli) 
strains C43 (DE3) and BL21 (DE3) were obtained from Novagen (Darmstadt, Germany). 
Fatty acids and flavanone were obtained from Sigma Aldrich (Schnelldorf, Germany). All 
other chemicals were purchased from standard sources and of the highest purity available.  
 
Expression and purification of CYP267B1 and its heterologous redox partners 
 
The construct of pET22b_CYP267B1 encoding the cyp267b1 gene from Sorangium 
cellulosum So ce56 (including a C’ terminal His6-tag) (GenBank: CAN97336.1) [25] was 
transformed into E. coli C43 (DE3) cells and grown overnight at 37°C in NB-I medium 
containing 100 µg/mL ampicillin (150 rpm). Subsequently, 2 L baffled Erlenmeyer flasks, 
each filled with 0.4 L of Terrific Broth (TB) medium (with 100 µg/mL ampicillin), were 
inoculated (1:100) with that overnight culture, and incubated at 37°C at 90 rpm, until OD600 
reached 0.8-1. Then the temperature was set to 28°C and 1 mM IPTG and 0.5 mM δ-ALA 
were added to induce the expression and support heme synthesis, respectively. Cells were 
harvested after 48 h by centrifugation for 30 min at 4500 g. Collected pellets were then stored 
at -20°C. Purification procedure started with pellet resuspension in 25 mM Tris (pH 7.4) 
buffer containing 0.5 mM EDTA, 10 mM NaCl and 1 mM phenylmethylsulfonyl fluoride 
(PMSF). The cells were lysed by sonication for 15 min on ice, followed by a centrifugation 
step for 45 min at 75000 g, at 4°C. The supernatant was loaded onto Ni-NTA column and 
washed with 25 mM Tris (pH 7.4) buffer containing 0.1 mM EDTA, 0.1 mM dithioerythritol 
(DTE) and 5 mM histidine. The elution was performed with the same buffer, but containing 
150 mM histidine. Red-colored fractions were pooled and dialyzed against 1 L of 25 mM 
Tris (pH 7.4) buffer containing 0.1 mM EDTA and 10 mM β-mercaptoethanol. Dialysis 
buffer was exchanged after 2 h and 16 h, respectively. The protein solution was then 
concentrated and loaded onto Superdex 75 column equilibrated with 25 mM Tris (pH 7.4) 
buffer containing 2% glycerol. In order to prepare substrate-bound complexes for 
crystallization, the buffer used during size-exclusion chromatography step was supplemented 
with 100 µM of the corresponding substrate (added from a 10 mM stock solution in dimethyl 
sulfoxide (DMSO)). Finally, intensively red colored fractions showing a spin state shift 
towards 390 nm in the measured UV-visible absorbance spectrum (or only a small shoulder 
as in case of flavanone) were concentrated and flash frozen with liquid nitrogen. The pure, 
aliquoted samples of CYP267B1 were stored at -80°C until further use.  
The redox partner proteins used in this work, a truncated form of bovine adrenodoxin 
(Adx4-108) and adrenodoxin reductase (AdR) were expressed and purified as described 
previously [27,28].   
 
Substrate binding assay and determination of dissociation constants (Kd) 
 
Substrate-induced spin state shifts were estimated using tandem quartz cuvettes, a double-
beam spectrophotometer (UV-2101PC, Shimadzu, Japan) and performing the binding assay 
as described elsewhere [29]. Purified CYP267B1 (5 µM) was dissolved in 20 mM potassium 
phosphate buffer (pH 7.4) and titrated with increasing concentrations of the corresponding 
substrate from either 1.0 or 10 mM stock solution in DMSO. Difference spectra were 
recorded from 350 to 500 nm. In order to determine the dissociation constant (Kd), the 
averaged peak-to-trough absorbance differences (ΔAmax) were plotted against increasing 
substrate concentration. Plots of dodecanoic and tetradecanoic acid were fitted with Origin 
8.6 software (OriginLab Corporation, Northampton, MA) by tight binding quadratic equation 
[ΔA =(Amax/2[E]){(Kd+[E]+[S])-{(Kd+[E]+[S])
2– 4[E][S]}1/2}], whereby ΔA represents the 
peak-to-trough absorbance difference at every substrate concentration, Amax is the maximum 
absorbance difference at saturation, [E] is the enzyme concentration, and [S] is the substrate 
concentration. The plot of decanoic acid was fitted by hyperbolic regression [ΔA 
=(Amax[S]/Kd+[S])] using Origin 8.6 software. All titrations were performed in triplicate.   
In vitro conversions 
 
A protein ratio of CYP: Adx: AdR of 1: 10: 3 (for fatty acids) or 1: 20: 3 (for flavanone) was 
used in a reconstituted in vitro system consisting of purified CYP267B1 (0.5 µM), Adx4-108 (5 
µM/ 10 µM), AdR (1.5 µM), MgCl2 (1 mM), glucose-6-phosphate (5 mM) and glucose-6-
phosphate dehydrogenase (1U) in a final volume of 250 µL of potassium phosphate buffer 
(20 mM, pH 7.4) was used. The substrates (dissolved in DMSO) were added to a final 
concentration of 200 µM. The reactions were initiated by addition of 500 µM NADPH. After 
30 min at 30°C the reactions were quenched. 500 µL of ethyl acetate (EtOAc) were used 
twice to extract flavanone and its conversion products. The combined organic phases were 
evaporated in vacuum and prepared for further analyses. The reactions of the fatty acids were 
stopped by adding 20 µL of 37% HCl, extracted with 1 mL diethyl ether, dried over 
anhydrous MgSO4 and the organic phase was evaporated. The residues were dissolved in 
40 µL N,O-bis(trimethylsilyl)trifluoroacetamide containing 1% trimethylchlorosilane and 
incubated for 30 min at 80°C before analysis. A negative control with none CYP added was 
performed for each substrate to verify the P450-dependent reaction. 
 
Whole-cell conversions  
The whole-cell reaction for the conversion of flavanone was performed as described 
previously [26]. The E. coli BL21 (DE3) cells were transformed with two plasmids, one 
encoding CYP267B1 (pET22b_CYP267B1) and one encoding the autologous redox partners 
from S. cellulosum So ce56, FdR_B (Ferredoxin-NADP
+
 reductase) and Fdx8 (Ferredoxin 8) 
(pCDF_F8B). After 21 hours of protein expression in 1 L scale (5x 200 mL in 2 L baffled 
flasks), 200 µM flavanone were added and incubated for 48 hours at 30°C, followed by 
extraction with the same volume of EtOAc. The extraction step was repeated, the organic 
phases were pooled and evaporated to dryness. The crude extract was stored at 4°C until 
further purification.  
Product purification was performed by column chromatography using silica gel with a 
mobile phase consisting of hexane and ethyl acetate (95:5).  Fractions were collected and 
analyzed by thing layer chromatography (TLC) using anisaldehyde staining for visualization. 
Product containing fractions were pooled, evaporated to dryness and dissolved in CDCl3 for 
NMR analysis. 
 
Product profile analysis by GC-MS and HPLC   
Analysis of the product profile and detailed characterization of hydroxylated fatty acid 
products was performed via gas chromatography-mass spectrometry (GC-MS) as described 
previously [12]. Briefly, the dried residue was dissolved in 35 μL of 
N,O-bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorsilan and incubated at 80C 
for 30 min to produce derivatized products prior to analysis. The analysis of products was 
carried out on a GC-MS-QP2010 (Shimadzu, Tokyo, Japan), equipped with a FS-Supreme-5 
column (30 m × 0.25 mm × 0.25 μm; Chromatographie Service, Langerwehe, Germany). A 
0.5 μL sample was injected for analysis using a split of 30. The purge flow was 3 mL/min 
(column flow = 0.61 mL/min), with helium as the carrier gas. The column temperature was 
maintained at 160C for 1 min, ramped to 260C at a rate of 10C/min, then to 300C at a 
rate of 40C/min and held for 3 min. The hydroxylated fatty acid products were identified by 
their specific fragmentation pattern in the silylated form, in which mainly two major 
fragments were considered.   
The reaction mixtures resulting from flavanone conversions were analyzed via HPLC. 
The system used combined a PU-2080 HPLC pump, an AS-2059-SF autosampler, a MD-
2010 multi wavelength detector (Jasco, Gross-Umstadt, Germany) and a Nucleodur 100–5 
C18 column (5 μM, 4.0 x 125 mm, Macherey–Nagel, Düren, Germany) thermostated at 40°C. 
Mobile phases consisted of 10% (v/v) acetonitrile in water (A) and pure acetonitrile (B). For 
analysis, a linear gradient from 10 to 80% of B (for 30 min) was used, followed by a linear 
gradient to 100% B for 10 min. Then the column was equilibrated with 10% of B for 5 min. 




NMR spectra were recorded with a Bruker DRX 500 (Rheinstetten, Germany) NMR 








H-COSY, HSQC and HMBC was used to 
elucidate the structure. All chemical shifts are relative to CHCl3 (δ=7.24 for 
1
H NMR) or 
CDCl3 (δ=77.00 for 




The samples of CYP267B1 co-purified with substrates (either flavanone or tetradecanoic 
acid) were thawed and concentrated further from ~20-35 mg/mL to ~60-70 mg/mL for 
crystallization trials, as lower protein concentrations did not result in crystal formation. 
Sitting-drop vapor-diffusion method was used for the search of the crystallization growth 
conditions. The Mosquito crystallization robot (TTP LabTech) aided to prepare 
crystallization drops consisting of 100 nL : 100 nL, protein : reservoir ratio, that were set up 
against 50 µL of reservoir solution in 96-well MRC2 crystallization plates. The initial 
crystals grew from 35% (v/v) Tacsimate reagent (pH 7.0) after approximately 3 days of 
equilibration at 293 K. Crystals were then optimized manually by using the hanging-drop 
vapor diffusion method, performed in 24-well plates carrying 500 µL of reservoir solution. 
Optimized drops consisted of 2 μL protein and 2 μL reservoir solution. Single, red crystals 
grew within approximately 1 week of equilibration at 293 K, from 36% (v/v) Tacsimate 
reagent (pH 7.0).  
 
Data collection and structure determination  
 
Prior to data collection, the crystals were briefly passed through a drop of 70% (v/v) 
Tacsimate reagent (pH 7.0), serving as a cryo-protection solution and flash-cooled in the 
110K-cold nitrogen gas cryostream. The data were collected at the European Synchrotron 
Radiation Facility (ESRF) in Grenoble, France (MX beamline ID29). The datasets were 
indexed and integrated using XDS [30], while scaling and merging was done with AIMLESS 
from the CCP4 software suite [31]. The structures were solved by the molecular replacement 
method and partially refined using the Auto-Rickshaw software pipeline [32], taking 
advantage of availability of the high-resolution data. The model of the P450 PikC 
(CYP107L1) D50N mutant (PDB entry 4UMZ, chain B) served as a search model (44 % 
sequence identity). Protein molecules in the crystals packed with 36% solvent content and the 
structures were solved in an orthorhombic space group (P212121), containing 1 molecule per 
asymmetric unit. The initial, partially refined models of CYP267B1 were then further refined 
by performing iterative cycles of model building in COOT [33] and refinement with 
Phenix.refine [34]. During last refinement rounds the waters and/or substrates were added to 
the models. Final model validation was carried out with Molprobity incorporated in the 
PHENIX software [35]. The final model coordinates and structure factor amplitudes were 
deposited in the Protein Data Bank (PDB): 6GK5 (CYP267B1) and 6GK6 (CYP267B1-
MYR).     
 
Molecular docking and structure analysis  
Selected ligands were docked into the active site of CYP267B1 structure (receptor) with the 
use of Autodock Vina 1.1.2 [36]. The receptor model had all crystallographic waters removed 
prior to docking experiments. Coordinates for fatty acids and drug molecules were taken 
from the available crystal structures: decanoic acid (DKA, PDB entry 5IBO), dodecanoic 
acid (DAO, PDB entry 5UCA), tetradecanoic acid (MYR, PDB entry 4TKH), diclofenac 
(DIF, PDB entry 4UBS) and ibuprofen (IZP, PDB entry 3R8G). For flavanone, a SMILES 
string taken from PubChem (PubChem CID: 10251) was converted into PDB coordinates 
using the CACTUS web server (https://cactus.nci.nih.gov) and the ligand geometry was then 
optimized with PRODRG2 web server [37]. For all ligands, the correct number of rotatable 
bonds was confirmed by manual inspection in AutoDockTools 1.5.6. Hydrogens and 
Gasteiger charges were also added in the above-mentioned software. The protein was kept 
rigid during docking and the simulation cell consisted of a grid box, centered at the heme-
iron, and covering the whole distal heme pocket (x:36 Å, y:46 Å, z:34 Å). Exhaustiveness 
parameter was default (= 8) for the fatty acids and set to 48 for the remaining three substrates. 
Binding poses were analyzed according to lowest binding energies and distances of the target 
oxidation sites in the ligand to the heme-iron.  
Pairwise structural alignments were performed with PDBeFold [38]. Identification of 
substrate recognition sites (SRS) in CYP267B1 (UniProt: A9ERX9) was done by sequence 
alignment with P450cam (UniProt: P00183) and according to description provided by Gotoh 
[39]: SRS1: 70-95 (B-C loop), SRS2: 171-177 (C’ terminal part of F helix), SRS3: 183-194 
(N’ terminal part of G helix), SRS4: 231-249 (central part of I helix), SRS5: 286-296 (K-β2 
connection) and SRS6: 390-397 (β3-hairpin). Substrate binding residues were analyzed in 
AutoDockTools 1.5.6 and LigPlot+ [40]. The molecular surface of the inner active site cavity 
was calculated by ‘3V: Voss Volume Voxelator’ web server and using 1.4 Å inner probe 
radius [41]. All structural figures were prepared using UCSF Chimera [42]. QR codes in 
selected figures allow to inspect the image in 3D on a smartphone or tablet, by means of the 





Identification of new substrates for CYP267B1: binding and conversion 
 
Even though CYP267B1 was already shown to bind and convert a variety of different 
substrates, it is of interest to further map its substrate scope and test new substrate classes for 
their potential to be converted. Of special interest are fatty acids (FAs) due to their 
biotechnological importance. Besides FAs, we also focused on flavonoids, which have a 
similar molecular mass as FAs but differ in chemical structure, and represent a large family 
of natural compounds with broad possibilities for application.  
To prepare the enzyme for substrate-binding and conversion experiments, the 
CYP267B1 from Sorangium cellulosum So ce56 was recombinantly expressed in E. coli and 
purified by a two-step procedure involving affinity chromatography followed by size-
exclusion chromatography, yielding about 300 nmol protein per liter of expression culture. 
Protein purity was evaluated by SDS-PAGE (Supplementary Figure 1) and the purified 
enzyme showed its typical spectral properties as reported previously [26].  
Next, it was tested whether the enzyme can accept FAs as substrates. The regioselective 
enzymatic oxidation catalyzed by P450s producing hydroxy-fatty acids (hydroxy-FAs) is a 
highly desired biocatalytic process, as hydroxy-FAs have many applications in the chemical, 
pharmaceutical, cosmetic or food industries [44,45]. Hydroxylated FAs are more stable and 
solvent miscible in comparison to their non-hydroxylated counterparts [46]. Use of hydroxy-
FAs in the synthesis of resins and polymers allows to obtain more flexible and more resistant 
final products in comparison to those derived from petroleum [47]. FAs are natural substrates 
of many P450s and, most interestingly, previous bioinformatic analysis indicated that 
CYP267B1 clusters well with the known FA-hydroxylating P450 enzymes [21]. Moreover, 
the closely related CYP267A1 (43% sequence identity) was recently shown to convert 
medium- to long-chain saturated FAs [48]. Indeed, we found that CYP267B1 is able to bind 
three different medium-chain FAs, i.e., decanoic acid (capric acid), dodecanoic acid (lauric 
acid) and tetradecanoic acid (myristic acid), as indicated by characteristic perturbations of the 
heme spectrum (a ‘type I’ shift of the Soret band from 418 nm towards 390 nm). Taking 
advantage of the substrate-binding induced spectral changes, dissociation constants (Kd) were 
determined for all three FAs (Table 1, Supplementary Figure 2), revealing that CYP267B1 
has a relatively strong affinity for tetradecanoic acid (Kd = 2.1 ± 0.7μM) and weaker affinities 
for the two other (shorter) FAs (Kd = 44 ± 4.0 μM and 13 ± 1.0 μM for decanoic acid and 
dodecanoic acid, respectively). In comparison, CYP267A1 displays a very weak affinity for 
tetradecanoic acid (Kd could not be measured), but its affinity for decanoic acid and 
dodecanoic acid binding is stronger compared to CYP267B1 (Kd values of 2.97 ± 0.24 μM 
and 1.05 ± 0.01 μM, respectively) [48].  
Next, flavanone (IUPAC: 2-phenyl-2,3-dihydrochromen-4-one) was investigated as a 
potential substrate of CYP267B1. This flavonoid compound is similar to tetradecanoic acid  
in molecular weight (224.3 g/mol versus 228.4 g/mol), but displays a completely different 
chemical structure (Supplementary Figure 3). Flavonoids are a large and diverse group of 
polyphenolic chemical compounds originating from plant sources [49]. They possess a three-
ring structure usually decorated with different substitutions that promote their various 
antioxidant, anti-inflammatory, anti-allergic or anti-carcinogenic roles [50,51]. The flavanone 
structure is known to serve as precursor to different flavonoid structures so that it can be 
expected that its specifically oxidized P450-generated bioconversion products are valuable 
intermediates for the chemical or pharmaceutical industry. Like with the FAs, titrations of 
CYP267B1 with flavanone resulted in ‘type I’ heme spectral changes, indicating binding of 
the flavonoid (Supplementary Figure 4). The induced perturbations to the heme spectrum 
were much smaller than for the FAs (below 10% of the maximum spin shift), indicating that 
flavanone binding by CYP267B1 is weak, and a dissociation constant could not be measured.  
After demonstrating their binding to CYP267B1, the three FAs and flavanone were 
subjected to in vitro conversion experiments. Truncated bovine adrenodoxin (Adx4-108) and 
adrenodoxin reductase (AdR), shown before to support the functional activity of CYP267B1 
as heterologous redox partner proteins [25], were applied to reconstitute the activity of the 
enzyme. All four tested substrates were converted in vitro by CYP267B1, with conversion 
ratios of 76%, 99%, 90% and 28% for decanoic acid, dodecanoic acid, tetradecanoic acid and 
flavanone, respectively. Taken together, it can be stated that two novel classes of CYP267B1 
substrates were found, medium-chain FAs and a flavonoid compound. Subsequent 
investigations concentrated on the identification of formed products.   
 
In-chain fatty acid hydroxylation by CYP267B1    
 
GC-MS analysis of the product mixtures resulting from FA conversions by CYP267B1 
revealed that the enzyme preferentially oxidized the inner carbon atoms of the FA chains and 
generated mono-hydroxylated products (Figure 1, Table 1). The three FAs are rather 
unselectively hydroxylated at their inner chain carbon atoms, with the highest regioselectivity 
exhibited towards decanoic acid (42% hydroxylation in -3 position). When using 
tetradecanoic acid, the formation of 28% ω-3 and 35% ω-4 hydroxylated metabolites was 
obtained (Table 1). The in-chain FA hydroxylations (occurring at positions between the 
methyl and carboxylate terminal carbons) are relatively common among bacterial P450s, 
usually resulting in a range of positions being hydroxylated during catalysis and multiple 
products being formed [52]. With increasing chain length of the FA substrate the 
regioselectivity of hydroxylation catalyzed by CYP267B1 is shifted from positions located 
closer to the methyl terminal carbon of the FA (ω-1, ω-2, ω-3) towards the inner-chain 
positions (ω-3 and ω-4). A relatively similar tendency to hydroxylate longer FAs at the 
further progressing inner-chain positions was previously reported for CYP276A1 from the 
same organism [48].   
Regioselective hydroxylation of flavanone by CYP267B1  
 
The in vitro conversion of flavanone by CYP267B1 resulted in one major product (P1, 15%) 
and some undefined side products (P2-P5) as detected by HPLC analysis (Figure 2A). In 
order to identify the products by NMR analysis, the previously established E. coli-based 
whole-cell system was used to scale-up the flavanone conversion [26]. In the applied in vivo 
system CYP267B1 was supported by an autologous redox partner pair, the FdR_B 
(Ferredoxin-NADP
+
 reductase) and Fdx8 (Ferredoxin 8) from Sorangium cellulosum So 
ce56. As a result, about 40% of 200 μM flavanone was converted within 24 h (Figure 2B). 
The resulting product profile was similar to the one observed in vitro, with one major product 
(P1, 21%), one side product (P5) and three minor side products (P2, P3 and P4). For NMR 
analysis only the P1 product was obtained in sufficient amounts (~10 mg), and by revealing a 
secondary hydroxyl group it was identified as 3-hydroxyflavanone  (Supplementary Table 1). 
The H2 and H3 protons showed a coupling constant of 12.3 Hz leading to the conclusion that 
the product exhibits a trans configuration around the C2-C3 bond, in agreement with the 
literature data [53] (Figure 2C).  
Biosynthesis of differently hydroxylated flavonoids is of high interest considering the 
difficulty of their extraction from plant sources or the necessity for complicated procedures to 
obtain them synthetically. Several papers have reported flavonoid hydroxylations catalyzed 
by P450s from mammals [54], plants [55], bacteria [56] or fungi [57]. To the best of our 
knowledge, production of 3-hydroxyflavanone with flavanone as substrate was only reported 
recently, in a whole-cell system expressing CYP110E1 from Nostoc sp. strain PCC 712; 
however, the final product co-existed with other side products and its final yields were not 
given [58]. Therefore, the myxobacterial CYP267B1 characterized in this work offers a new 
biocatalytic route to regioselective production of 3-hydroxyflavanone.   
 
Overall structural features of CYP267B1     
 
To gain insights into the structural basis of binding and regioselective conversion of 
flavanone and FAs by CYP267B1, the protein-substrate complexes were analyzed by X-ray 
crystallography. Protein samples were co-purified with flavanone or tetradecanoic acid and 
screened for suitable crystallization growth conditions. Tetradecanoic acid was selected for 
crystallographic binding analysis, considering that among the three tested FAs it contains the 
longest fatty acid chain and displayed the highest binding affinity. Crystals of CYP267B1 in 
the presence of flavanone or tetradecanoic acid grew at identical conditions using highly 
concentrated protein samples (~70 mg/mL). Crystal structures were determined by the 
molecular replacement method and refined at 1.6 Å resolution in the P212121 space group, 
with the asymmetric unit containing one protein molecule (see Table 2 for relevant 
crystallographic statistics). In both structures an ordered water molecule is occupying the 
sixth coordination position of the heme-iron. Additional clear density for a bound substrate 
was only visible in the case of tetradecanoic acid. In the structure obtained from a crystal 
grown in the presence of flavanone, the density for the flavanone molecule was very weak 
and the substrate could not be modeled. The two structures (CYP267B1 and CYP267B1-
MYR) are highly similar, displaying a root mean square deviation [r.m.s.d] in Cα-backbone 
positions of 0.09 Å. The polypeptide chain is well resolved in the electron density maps, 
except for the first five N-terminal residues and most of the C-terminal His6-tag, which 
appear disordered and were left out from the models. 
The overall structure of CYP267B1 shows the characteristic fold for the P450 
superfamily, with 16 α-helices and 3 -sheets (1 two-stranded and 2 three-stranded -sheets) 
(Figure 3). The heme iron is ligated to the conserved cysteine residue (Cys354) and the heme 
is further stabilized by several hydrophobic/van der Waals interactions with neighboring 
residues in the heme-binding pocket, and by ionic interactions of its propionates with the side 
chains of His99, Arg103, His352 and Arg296. The overall protein structure adopts a “closed” 
conformation, with the F and G helices and the F-G loop (loop connecting the helices F and 
G) topping the active site pocket and making it almost inaccessible to the solvent. According 
to a structural alignment performed against the whole PDB archive, the structure of 
CYP267B1 shows the highest match to “closed” crystal structures of PikC, another P450 
accepting macrolides as substrates [59], (Figure 4A, Supplementary Table 2). Similar to 
PikC, the inner active site cavity of CYP267B1 is very spacious, consistent with its ability to 
accept a great variety of substrate sizes, ranging from very small ones like α-ionone [22] to 
large macrocyclic compounds such as epothilone D [24]. Towards the heme the pocket 
narrows, restricting access to the heme-iron, in particular due to the presence of residue 
Leu92 located in the substrate recognition site 1 (SRS1) (Figure 4B). This residue 
corresponds to Phe87 in P450 BM3, and likely is similarly important for determining the 
substrate range and regioselectivity of hydroxylation [60]. Another residue in the SRS1 
region of CYP267B1, His90, may further influence the regioselectivity of substrate 
hydroxylations. This is evident from comparing the structure of CYP267B1 with that of P450 
EpoK, an enzyme from Sorangium cellulosum So ce90 involved in epothilone biosynthesis 
[61]. Both enzymes convert epothilone D, but a superposition with the structure of epothilone 
D-bound EpoK reveals that this substrate cannot adopt the same binding mode in the active 
site pocket of CYP267B1, due to a clash with His90 (Figure 4B). This difference may be 
related to previous observations that these enzymes convert epothilone D with quite different 
regioselectivities: while EpoK converts epothilone D exclusively to epothilone B, CYP267B1 
oxidizes epothilone D to 5 different products [24]. The large pocket of CYP267B1 likely 
allows epothilone D to adopt several alternate binding modes resulting in the broad 
regioselectivity. The current crystal structure may help future engineering of CYP267B1 
towards improved regioselective conversion of epothilone D, similar as done recently for 
P450 BM3 and the macrocylic substrate β-cembrenediol [62].  
 
 
CYP267B1-tetradecanoic acid complex and prediction of fatty acid binding modes  
 
As mentioned above, the extra electron density in the CYP267B1-MYR crystal structure 
allowed us to model a bound substrate (Figure 5A). The electron density displayed a 
continuous U-shape, consistent with a curved binding mode of the fatty acid. The ends of the 
electron density were not very clearly defined, though, therefore it was considered that MYR 
did bind in two alternative binding orientations (each modeled with 50% occupancy), either 
with its carboxylate end towards SRS1 (purple conformer, Figure 5B) and stabilized by a 
water-mediated hydrogen bond with His90, or towards SRS5/SRS6 (pink conformer, Figure 
5B), forming several water-mediated interactions with the backbone atoms of Glu291, 
Leu292, Ser293, Pro393 and Thr394. In both binding modes, MYR forms hydrophobic 
interactions with Leu92 (SRS1); Leu176 (SRS2); Val242, Ala243, Thr247 (SRS4); Ala290, 
Leu292 (SRS5) and Pro393 (SRS6) (Figure 5B). The orientation of MYR relative to the 
heme-iron points to predominant oxidation at the C7 or C8 carbon atoms of tetradecanoic 
acid (3.9-4.2 Å distance to the heme-iron in both binding modes), suggesting ω-6/ ω-7 
hydroxylation, which is not observed experimentally. Thus, the alternate binding modes of 
MYR, while consistent with the electron density, are non-productive. It is not uncommon for 
FAs to be bound in non-productive conformations in P450 crystal structures: this has been 
observed previously in the palmitoleic acid-bound P450 BM3 structure [63] or the lauric 
acid-bound structure of CYP107L2 from Streptomyces avermitilis [64]. Moreover, the 
presence of the heme-bound water in the CYP267B1-MYR structure further indicates that the 
enzyme adopts a ‘resting’ state (low-spin heme-Fe); in order to reach the ‘active’ state during 
catalysis the substrate needs to displace this water molecule.  
To predict plausible ‘active’ binding conformations of the three FA substrates 
identified in this work, docking calculations were performed with the crystal structure of 
CYP267B1. For each FA twenty binding poses were generated and ranked according to their 
lowest predicted binding energies. It was found that in great majority (14-16 out of 20 
binding poses) FAs were predicted to bind in the top parts of the active site (between the 
central part of the B-C loop and the F helix/F-G loop). Only about 4-6 poses placed the 
individual FA relatively close to the heme, and among those only 3-4 poses had one or more 
carbon atoms at a distance suitable for hydroxylation. From those latter FA binding poses, the 
ones with the lowest predicted binding energies were selected for further analysis. Decanoic 
acid is predicted to bind with its carboxylate group in hydrogen bonding distance to His90 
(SRS1) and interact with several active site residues like Leu92 (SRS1); Thr247, Ala243, 
Leu239, Val242 (SRS4); Ala290 (SRS5); Ile395 (SRS6). Its omega end is curved over the 
heme exposing the C7, C8, C9 carbon atoms for hydroxylation (Figure 6A). A very similar 
binding pose was obtained when dodecanoic acid was docked into the CYP267B1 active site, 
although its carboxylate group is too far from His90 (SRS1) to form a hydrogen bond (3.6 
Å). Dodecanoic acid is predicted to interact with a similar set of residues: Leu92 (SRS1); 
Leu176 (SRS2); Phe238, Leu239, Val242, Ala243, Thr247 (SRS4); Ala290, Pro289 (SRS5) 
and Ile395 (SRS6). In such a predicted binding conformation the C7, C8, C9, C10 and C11 
carbon atoms are most optimally located for hydroxylation (Figure 6B). In contrast to 
decanoic and dodecanoic acid binding, tetradecanoic acid docks in a distinct flipped 
orientation towards the SRS5/SRS6 residues and its pose resembles one of the alternative 
conformers found in the CYP267B1-MYR crystal structure. No hydrogen bonds are 
predicted to stabilize the bound MYR and the long molecule forms several hydrophobic 
interactions with residues in majority belonging to SRS4 and SRS5: Leu92 (SRS1); Ala243, 
Val242, Thr247, Leu239 (SRS4); Thr294, Leu292, Ser293, Ile295 (SRS5) and Pro393, 
Ile395 (SRS6). Importantly, the predicted MYR binding mode positions carbon atoms C9, 
C10, C11 and C12 at a close distance from the heme-iron (Figure 6C), consistent with its 
observed hydroxylation pattern.  
Thus, our results demonstrate that the closed protein conformation displayed by the 
CYP267B1 crystal structure allows prediction of plausible ‘productive’ binding poses for 
each of the three FAs. The FAs bind with their omega-end bended over the heme, positioning 
different carbon atoms near to the heme-iron. The observed hydroxylation patterns are 
consistent with a very spacious active site pocket and lack of strong hydrogen bonding 
interactions, making it difficult for CYP267B1 to strictly control the conformation and 
position of the flexible FA chain within its active site. In contrast, terminal FA hydroxylases 
(ω-hydroxylases) like CYP153A from Marinobacter aquaeolei [65], which are highly 
regioselective, display a narrow hydrophobic tunnel for binding FAs, restricting substrate 
motility in their active site. Likely, all in-chain FA hydroxylating P450s display similar active 
site properties as CYP267B1, explaining why so far no ‘exclusive P450 in-chain 
hydroxylase’ has been reported [52].  
 
Prediction of flavanone binding mode  
 
Using similar procedures also flavanone was docked into the active site of CYP267B1. 
Flavonone, like the docked FAs, preferred binding in the top parts of the active site (13 out of 
20 poses). Nevertheless, among the binding poses close enough to the heme for 
hydroxylation the one with the lowest predicted binding energy was consistent with the major 
oxidation site at carbon C3 (Figure 6D). This productive binding pose of flavanone is 
stabilized by hydrogen bonding of its C4-carbonyl group to the backbone amide nitrogen of 
Ala243 (SRS4) and by hydrophobic interactions with the side chains of Leu176 (SRS2); 
Phe238, Leu239, Val242, Thr247 (SRS4); Ala290, Thr294 (SRS5) and Ile395 (SRS6). 
Importantly, the C3 carbon is oriented towards the heme-iron such that hydroxylation would 
lead to a trans-configuration around the C2-C3 bond, which is perfectly in agreement with 
our experimental data (Figure 6D).  
 
Molecular docking of diclofenac and ibuprofen  
Considering the clear results obtained from the docking calculations with flavanone and the 
three FAs, we were wondering whether the crystal structure of CYP267B1 also allowed 
plausible productive binding modes to be predicted for other known CYP267B1 substrates 
with a characterized product profile. Thus, two drug molecules, diclofenac and ibuprofen, 
were docked into the active site of CYP267B1, and for both substrates low energy binding 
poses were identified (Figure 7) which showed good agreement with the previously identified 
protein activity for formation of 4’-hydroxydiclofenac and 2-hydroxyibuprofen as main 
products, respectively [26]. Diclofenac is predicted to expose the C4’ carbon for oxidation 
and to interact with Leu92 (SRS1); Leu176 (SRS2); Leu292, Ser293, Thr294 (SRS5) and 
Pro393, Thr394, Ile395 (SRS6) (Figure 7A). The ibuprofen molecule is predicted to form one 
hydrogen bond with His90 (SRS1) and be further stabilized by Leu92 (SRS1); Leu176 
(SRS2); Phe238, Leu239, Val242, Ala243 (SRS4); Ala290 (SRS5) and Ile395 (SRS6) 
(Figure 7B).  
In conclusion, the present study identified two novel substrate classes to be converted 
by the broad substrate range enzyme, cytochrome P450 CYP267B1 from Sorangium 
cellulosum So ce56. It was shown to oxidize medium-chain fatty acids and flavanone. For the 
first time a three-dimensional structure of this versatile enzyme was determined, allowing to 
dock several substrates identified in this work and before, and to predict plausible productive 
conformations. However, in order to predict the reaction products more precisely in the future 
(e.g. from substrates with unidentified product profiles), more sophisticated bioinformatic 
methods could be employed like molecular dynamics (MD) simulations or combined 
quantum mechanical/molecular mechanical (QM/MM) calculations (also involving the heme 
oxoferryl moiety). Thus, the structure of CYP267B1 will likely inspire future rational 
mutagenesis-based adaptations of this protein towards different biotechnological applications.  
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Table 1: Substrate binding affinity and product distribution of saturated fatty acid conversion 









-7 -6 -5 -4 -3 -2 -1 
Decanoic acid (C10:0) 44 ± 4.0 - - - 5 42 19 17 
Dodecanoic acid (C12:0) 13 ± 1.0 - <0.5 13 25 36 20 5 
Tetradecanoic acid (C14:0) 2.1 ± 0.7 1 3 14 35 28 7 1 
Note:  a values are given as percent of the total product observed (mean of two individual experiments). -, not 
observed  
Table 2: Crystallographic data collection and refinement statistics of CYP267B1.  
 
    CYP267B1 CYP267B1-MYR  




Monomers in the AU 1 1 
 
Solvent content (%) 36 37 
 
Ligands n/a myristic acid (MYR) 
Data collection 
 
Beamline (ESRF) ID29 ID29 
 
Wavelength (Å) 0.97625 0.97625 
 
Resolution range (Å) 41-1.60 (1.63-1.60)a 41-1.60 (1.63-1.60) 
 
Space group P212121 P212121 
 
Unit-cell parameters  
  
a, b, c (Å) 51.50 66.39 104.30 51.80 66.65 104.52 
  
α, β, γ ° 90 90 90 90 90 90 
 
Observed reflections 175,537 (8,609) 169,339 (8,117) 
 
Unique reflections 45,694 (2,319) 47,055 (2,350) 
 
Multiplicity 3.8 (3.7) 3.6 (3.5) 
 
Completeness (%) 95.6 (95.1) 97.5 (99.0) 
 
<I/σ(I)> 18.6 (3.2) 10.4 (2.2) 
 
Rmerge (%) 3.0 (32.5) 5.5 (48.5) 
 
Rp.i.m. 2.3 (26.9) 4.1 (37.9) 
 
CC1/2 (%) 99.9 (83.7) 99.8 (67.6) 
Refinement 
 
Rwork (%) 18.7 18.7 
 
Rfree (%) 20.8 20.8 
 
R.m.s.deviation, bond lengths (Å) 0.019 0.015 
 
R.m.s.deviation, bond angles (°) 1.524 1.329 
 
Average B-factors  (Å)2 
  
  
Overall 31.0 31.4 
  
Protein 31.2 31.3 
  
Heme 20.8 20.9 
  
Myristic acid (MYR) n/a 42.5 
 
Ramachandran plot statistics 
  
  
Most favored (%) 96.8 97.0 
  
Allowed regions (%) 2.9 3.0 
  
Disallowed regions (%) 0.3 0 
  Molprobity overall score 1.31  1.36 








Figure 1: Gas chromatogram of ω-hydroxylation of decanoic acid (top), dodecanoic acid 
(middle) and tetradecanoic acid (bottom) catalyzed in vitro by CYP267B1. The ‘*’ represents 
impurities during GC-MS measurement. The insets show fatty acid chemical structures with 
green arrows indicating hydroxylation positions (with major ones shown in bold). 
 
Figure 2: Conversions of flavanone by CYP267B1. (A) HPLC chromatogram depicting the 
result of the CYP267B1-catalyzed in vitro conversion of flavanone. (B) HPLC  
chromatogram showing the result of the CYP267B1-catalyzed in vivo conversion of 
flavanone. ‘Sub’ designates the corresponding substrate. The main product (P1, tR= 24.2 min) 
was isolated, purified and analyzed via NMR spectroscopy. (C) Scheme showing the 
CYP267B1 catalyzed reaction of flavanone hydroxylation. The relative configuration (rel) of 
the C2-phenyl and C3-hydroxyl groups was determined as trans, based on the coupling 
constant of 12.3 Hz between the H2 and H3 protons.  
 
Figure 3: Overall fold of CYP267B1 from Sorangium cellulosum So ce56, colored from blue 
at the N’ terminus to red at the C’ terminus. The heme is shown as a red stick model in the 
center of the molecule. Helices are labeled A to L and three -sheets are indicated, following 
the common P450 nomenclature [66]. QR code allows to appreciate the figure in 3D [43].  
 
Figure 4: (A) Structural superposition of CYP267B1 in dark blue, with P450 PikC 
presenting a closed conformation (molecule A of PDB entry 2BVJ) in light blue, and PikC in 
an open conformation (molecule B of PDB entry 2BVJ) in magenta. (B) View of the inner 
active site cavity in CYP276B1. The solvent-accessible surface is shown as a semitransparent 
grey surface. A molecule of epothilone D as bound in the active site of P450 EpoK (PDB 
entry 1PKF) is superimposed for comparison and shows the steric hindrance caused by His90 
of CYP267B1. The heme is depicted as red stick model. QR codes allow to appreciate the 
figure in 3D [43].  
 
Figure 5: Tetradecanoic acid binding in CYP267B1. (A) Quality of electron density for the 
active site ligands in CYP267B1-MYR is depicted. Green mesh represents a composite 2Fo - 
Fc  omit map calculated at 1.6 Å resolution and contoured at 0.5 σ. Black mesh is the final 
2Fo - Fc  electron density map, contoured at 0.5 σ. (B) Two alternative binding orientations of 
tetradecanoic acid and its binding interactions with active site waters and protein residues. 
One of the conformers is shown in purple with carbon atoms numbered in black, whereas the 
other is depicted in pink and its carbon atoms are numbered in red. QR code allows to 
appreciate the figure in 3D [43].  
 
Figure 6: Molecular docking of fatty acids and flavanone in the active site of CYP267B1. 
(A) Decanoic acid is shown as an orange ball-and-stick model. (B) Dodecanoic acid is shown 
as ball-and-stick model, in green. (C) Tetradecanoic acid is depicted as ball-and-stick model 
in magenta. Carbon atoms are numbered in black. (D) Molecular model of flavanone binding 
in the active site of CYP267B1. The binding pose found closest to the heme and having 
lowest binding energy is shown, depicting a suitable conformation of flavanone (in cyan) for 
major hydroxylation event at carbon C3. Hydrogens are shown as white balls. The binding 
pose suggests generation of hydroxylation product being in trans configuration with the C2-
phenyl group, what is in good agreement with the experimental data. Heme is shown as red 
stick model. QR codes allow to appreciate the figure in 3D [43]. 
 
Figure 7: Molecular models of diclofenac and ibuprofen binding in the CYP267B1 active 
site. (A) Diclofenac is shown as light pink ball-and-stick model. (B) Ibuprofen is depicted as 
light blue ball-and-stick model. Both binding modes are consistent with the available 
literature data reporting generation of 4’-OH-diclofenac and 2-OH-ibuprofen by CYP267B1 
from Sorangium cellulosum So ce56. Heme is shown as red stick model.  QR codes allow to 
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Supplementary Table 1: NMR data for the main product of CYP267B1-catalyzed flavanone 
conversion, the 3-hydroxyflavanone.  
 
3-hydroxyflavanone (product P1) 
 
1H NMR (500 MHz, CDCl3): 7.91 (m, 1H, H5), 7.58 (m, 2H, H2’, H6’), 7.54 (m, 1H, H7), 
7.46 (m, 2H, H3’, H5’), 7.43 (m, 1H, H4’), 7.10 (m, 1H, H6), 7.04 (d, 1H, H8), 5.13 (d, 1H, 
H2, J= 12.3 Hz), 4.63 (d, 1H, H3, J= 12.3 Hz) 
 
 
13C NMR (125 MHz, CDCl3): 194.2 (C4), 161.7 (C8a), 136.9 (C7), 136.3 (C1’), 129.3 
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Supplementary Table 2: A summary of the top ten highest-ranked P450 structural 
homologues of CYP267B1 as evaluated by PDBeFold search  [1]. Additionally the result of a 
search against the PDB entry 2BVJ only is shown in grey. Nalign – number of matched 






Q score RMSD Cα [Å] Nalign % Seq P450 and organism 
1 4umz:B 0.71 1.52 378 44 PikC (CYP107L1) D50N, Streptomyces venezuelae 
 2bvj:A 0.70 1.61 378 44 PikC, closed conformation 
2 5cje:A 0.69 1.50 368 43 CYP107L2, Streptomyces avermitilis  
3 5l92:A 0.68 1.50 364 34 CYP109E1, Bacillus megaterium 
4 3ejd:H 0.66 1.62 361 40 BioI (CYP107H1), Bacillus subtilis 
5 3vrm:A 0.63 1.61 362 43 Vdh (CYP107BR1) T107A, Pseudonocardia autotrophica 
6 3a51:A 0.62 1.61 361 42 Vdh-K1 (CYP107BR1),  Pseudonocardia autotrophica 
7 5x7e:A 0.62 1.74 368 34 CYP105A1-R84A, Streptomyces griseolus 
8 1t2b:B 0.62 1.55 355 28 P450 CIN (CYP176A1), Citrobacter braakii 
9 3buj:A 0.62 1.82 369 32 CalO2, Micromonospora echinospora 
10 4ubs:A 0.62 1.80 365 37 CYP105D7, Streptomyces avermitilis 
 2bvj:B 0.57 1.71 345 46 PikC, open conformation 
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Supplementary Figure 2:  Type I spectral shifts induced by the binding of (A) decanoic 
acid, (B) dodecanoic acid and (C) tetradecanoic acid to CYP267B1. The peak-to-through 
absorbance differences are plotted against increasing substrate concentrations. The insets 
show type I spectral shifts induced by the binding of increasing amounts of substrate.  
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Supplementary Figure 3: The chemical strutures of flavanone (A) and tetradecanoic acid 
(B), with their respective molecular masses (MW) given.  
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Supplementary Figure 4:  Spectral perturbations observed upon titration of CYP267B1 with 
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